Actos Bladder Cancer Lawsuit: The first bellwether Actos lawsuit is scheduled to begin trial soon in U.S. District Court for the Western District of Louisiana. The actos lawsuit trial is scheduled to begin on January 27, 2014. The plaintiffs in this actos lawsuit, allege the use of Actos to treat type 2 diabetes from 2004 to 2011 led to a bladder cancer diagnosis in 2011.
In the Actos Bladder Cancer Lawsuit, the drug Actos is sold under the brand-name Actos ((pioglitazone) class of drugs which help to lower blood glucosue levels), may be sold in combination with metformin (Actoplus Met, Actoplus Met XR) and glimepiride (Duetact) and may be used along with diet and exercise to improve control of blood sugar in adults with type 2 diabetes mellitus.
However, studies have now shown long-term use of Actos can significantly increase a person’s risk for bladder cancer. In 2011, the FDA reported results from the first half of a 10-year study that showed patients who took higher doses of Actos for one year or longer increased their risk for bladder cancer by as much as 40%.
In addition, the the FDA website states that from January 2010 through October 2010, approximately 2.3 million patients filled a prescription for a pioglitazone-containing product from outpatient retail pharmacies. Actos has not been recalled by the FDA and is still on the market in the United States.
We are currently investigating claims involving the development of bladder cancer arising from the use of Actos. If you taken actos and developed bladder cancer, we can help you with your potential claim.
At the Gooch Law Firm, we pride ourselves on providing our clients reliable representation for even the most challenging cases. If you or a loved one took Actos and are now suffering from side effects related to Actos, including bladder cancer, contact our office at 1.844.329.5955.
WE ARE HERE TO HELP YOU PROTECT YOUR LEGAL RIGHTS